tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
12.925USD
+0.055+0.43%
Market hours ETQuotes delayed by 15 min
4.06BMarket Cap
725.31P/E TTM

Amneal Pharmaceuticals Inc

12.925
+0.055+0.43%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Amneal Pharmaceuticals Inc

Currency: USD Updated: 2025-12-24

Key Insights

Amneal Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 20/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.75.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amneal Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
20 / 158
Overall Ranking
57 / 4562
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
13.750
Target Price
+15.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amneal Pharmaceuticals Inc Highlights

StrengthsRisks
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.29% year-on-year.
Overvalued
The company’s latest PE is 722.22, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 154.72M shares, increasing 0.04% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 17.90M shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of Amneal Pharmaceuticals Inc is 8.57, ranking 54/158 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 784.51M, representing a year-over-year increase of 11.68%, while its net profit experienced a year-over-year increase of 1618.59%.

Score

Industry at a Glance

Previous score
8.57
Change
0

Financials

5.26

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

7.59

Amneal Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of Amneal Pharmaceuticals Inc is 8.19, ranking 25/158 in the Pharmaceuticals industry. Its current P/E ratio is 722.22, which is 40.59% below the recent high of 1015.40 and 156.34% above the recent low of -406.91.

Score

Industry at a Glance

Previous score
8.19
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 20/158
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of Amneal Pharmaceuticals Inc is 8.00, ranking 56/158 in the Pharmaceuticals industry. The average price target for Amneal Pharmaceuticals Inc is 13.50, with a high of 15.00 and a low of 13.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts
Buy
Current Rating
13.750
Target Price
+15.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Amneal Pharmaceuticals Inc
AMRX
5
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of Amneal Pharmaceuticals Inc is 9.53, ranking 8/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 13.33 and the support level at 12.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.51
Change
0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(1)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.046
Buy
RSI(14)
65.970
Neutral
STOCH(KDJ)(9,3,3)
86.904
Overbought
ATR(14)
0.306
Low Volatility
CCI(14)
127.919
Buy
Williams %R
9.170
Overbought
TRIX(12,20)
0.333
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
12.748
Buy
MA10
12.516
Buy
MA20
12.343
Buy
MA50
11.573
Buy
MA100
10.596
Buy
MA200
9.218
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of Amneal Pharmaceuticals Inc is 5.00, ranking 74/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 55.65%, representing a quarter-over-quarter decrease of 1.69%. The largest institutional shareholder is The Vanguard, holding a total of 17.90M shares, representing 5.69% of shares outstanding, with 13.57% increase in holdings.

Score

Industry at a Glance

Previous score
5.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Patel (Tushar Bhikhubhai)
48.58M
-9.33%
Patel (Chintu)
25.62M
+1.39%
Patel (Dipan)
23.83M
--
Patel (Chirag K)
22.13M
--
Akram (Mahesh)
20.56M
-23.45%
The Vanguard Group, Inc.
Star Investors
17.49M
+11.34%
Rubric Capital Management LP
11.71M
+9.08%
TPG Capital, L.P.
12.33M
--
BlackRock Institutional Trust Company, N.A.
10.64M
-4.49%
Citadel Advisors LLC
5.62M
-24.92%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of Amneal Pharmaceuticals Inc is 8.49, ranking 30/158 in the Pharmaceuticals industry. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
8.49
Change
0
Beta vs S&P 500 index
1.35
VaR
+4.69%
240-Day Maximum Drawdown
+22.64%
240-Day Volatility
+39.96%

Return

Best Daily Return
60 days
+8.20%
120 days
+8.20%
5 years
+22.32%
Worst Daily Return
60 days
-4.12%
120 days
-4.12%
5 years
-14.00%
Sharpe Ratio
60 days
+3.41
120 days
+3.09
5 years
+0.52

Risk Assessment

Maximum Drawdown
240 days
+22.64%
3 years
+49.40%
5 years
+82.74%
Return-to-Drawdown Ratio
240 days
+2.72
3 years
+3.12
5 years
+0.21
Skewness
240 days
+0.11
3 years
+1.38
5 years
+0.66

Volatility

Realised Volatility
240 days
+39.96%
5 years
+55.56%
Standardised True Range
240 days
+2.32%
5 years
+1.80%
Downside Risk-Adjusted Return
120 days
+531.09%
240 days
+531.09%
Maximum Daily Upside Volatility
60 days
+24.75%
Maximum Daily Downside Volatility
60 days
+19.50%

Liquidity

Average Turnover Rate
60 days
+0.52%
120 days
+0.57%
5 years
--
Turnover Deviation
20 days
+0.39%
60 days
-2.77%
120 days
+5.26%

Peer Comparison

Pharmaceuticals
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc
AMRX
8.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Amneal Pharmaceuticals Inc?

The TradingKey Stock Score provides a comprehensive assessment of Amneal Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Amneal Pharmaceuticals Inc’s performance and outlook.

How do we generate the financial health score of Amneal Pharmaceuticals Inc?

To generate the financial health score of Amneal Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Amneal Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Amneal Pharmaceuticals Inc.

How do we generate the company valuation score of Amneal Pharmaceuticals Inc?

To generate the company valuation score of Amneal Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Amneal Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Amneal Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Amneal Pharmaceuticals Inc.

How do we generate the earnings forecast score of Amneal Pharmaceuticals Inc?

To calculate the earnings forecast score of Amneal Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Amneal Pharmaceuticals Inc’s future.

How do we generate the price momentum score of Amneal Pharmaceuticals Inc?

When generating the price momentum score for Amneal Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Amneal Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Amneal Pharmaceuticals Inc.

How do we generate the institutional confidence score of Amneal Pharmaceuticals Inc?

To generate the institutional confidence score of Amneal Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Amneal Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Amneal Pharmaceuticals Inc.

How do we generate the risk management score of Amneal Pharmaceuticals Inc?

To assess the risk management score of Amneal Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Amneal Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Amneal Pharmaceuticals Inc.
KeyAI